



June 7, 2024

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Vide letter dated March 22, 2024, we had informed the Exchange as regards Lupin Limited ('the Company') having planned to enter into a Business Transfer Agreement ('BTA') with Lupin Life Sciences Limited ('LLSL'), wholly owned subsidiary of the Company, to carve out, its trade generics business in India, as a going concern, on a slump sale basis.

We are pleased to inform you that today i.e. June 7, 2024, the Company entered into a BTA with LLSL, in terms of which, the said carve out will be effective July 1, 2024.

This may kindly be considered as disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**